吗替麦考酚酯

  • 网络Mycophenolate mofetil;MMF
吗替麦考酚酯吗替麦考酚酯
  1. 吗替麦考酚酯(骁悉)可显著提高移植肾存活率。

    MMF can improve the graft survival significantly .

  2. HPLC法测定注射用吗替麦考酚酯的含量

    Determination the Content of Mycophenolate Mofetil for Injection by HPLC

  3. HPLC法测定吗替麦考酚酯有关物质优化条件评定研究

    Study on the selection of optimum condition for determination of mycophenolate mofetil by HPLC

  4. 两组患者术后1个月的肝功能比较:吗替麦考酚酯组患者的谷丙转氨酶升高发生率显著低于咪唑立宾组(13.3%,34.6%,P0.05);

    Liver function of the two groups one month after operation : The abnormal high glutamic-pyruvic transaminase in the Mycophenolate group was significantly lower as compared with Mizoribine group ( 13.3 % , 34.6 % , P 0.05 ) .

  5. 目的:观察吗替麦考酚酯(MMF)分散片联合泼尼松治疗难治性肾病综合征(RNS)的疗效性及安全性。

    OBJECTIVE : To evaluate the efficacy and safety of mycophenolate mofetil ( MMF ) plus prednisone on refractory nephrotic syndrome ( RNS ) in children .

  6. 在一些病例中,已发现随着吗替麦考酚酯的剂量减少或治疗的停止,PRCA具有可逆性。

    In some cases , PRCA was found to be reversible with dose reduction or cessation of CellCept therapy .

  7. 两组患者术后1个月的血常规、消化系统反应发生情况比较:吗替麦考酚酯组患者的白细胞降低(4×1012)发生率显著高于咪唑立宾组(26.7%,0,P0.05);

    Blood test and gastrointestinal reaction of the two groups one month after operation : The leukocytopenia ( 4 × 1012 ) rate of Mycophenolate group was significantly higher as compared with Mizoribine group ( 26.7 % , 0 , P 0.05 ) .

  8. 2篇RCT(共22例IMN患者)表明,吗替麦考酚酯联合糖皮质激素在降低蛋白尿方面与其他免疫抑制剂同样有效。

    Two RCTs with 22 patients showed that MMF therapy ( concomitant with corticosteroids ) was as effective as the comparative immunosuppressants to reduce proteinuria .

  9. 对于患有CRF的肝脏受体,减量或停用CNI的同时采用吗替麦考酚酯(骁悉)是安全的,其与肾功能的改善有关。

    In liver recipients with CRF , a reduction or withdrawal of CNI concomitantly with the introduction of MMF was safe and was associated with an improvement in renal function .

  10. 重症肌无力患者吗替麦考酚酯的血药浓度监测

    Therapeutic Drug Monitoring of Mycophenolate Mofetic in Patients of Myasthenia Gravis

  11. 吗替麦考酚酯联合泼尼松治疗难治性狼疮性肾炎的疗效观察

    Combined therapy of mycophenolate mofetil and prednisone for refractory lupus nephritis

  12. 吗替麦考酚酯治疗过敏性紫癜肾炎的护理体会

    On the Nursing of Henoch-Schonlein Purpura Nephritis Treated with Mycophenolate Mofetil

  13. 低剂量吗替麦考酚酯在直系亲属活体肾移植中的应用

    Application of low-dosage mycophenolate mofetil in living renal transplantation of lineal consanguinity

  14. 肾移植术后吗替麦考酚酯替换硫唑嘌呤的临床分析

    Clinical efficacy of azathioprine replaced with mycophenolate mofetil in renal transplant recipients

  15. 吗替麦考酚酯胶囊的人体生物等效性研究

    Bioequivalence of Two Oral Formulations of Mycophenolate Mofetil Capsule in Human Volunteers

  16. 吗替麦考酚酯分散片在中国健康男性志愿者体内的药动学和生物等效性研究

    Pharmacokinetics and bioequivalence of Mycophenolate Mofetil Dispersible Tablets in Chinese healthy male volunteers

  17. 吗替麦考酚酯片在男性健康志愿者体内生物等效性研究二、末日意识

    Bioequivalence of Two Oral Formulations of Mycophenolate Mofetil Tablet in Male Healthy Volunteer

  18. 吗替麦考酚酯胶囊在健康受试者人体内相对生物利用度和生物等效性研究

    Research on the Relative Bioavailability and Bioequivalence of Mycophenolate Mofetil Capsules in Healthy Volunteers

  19. 吗替麦考酚酯治疗弥漫增生性狼疮性肾炎的多中心临床研究

    Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis : a multicenter clinical trial in China

  20. 吗替麦考酚酯联合拉米夫定治疗乙型肝炎病毒相关性肾炎

    Clinical Study of Mycophenolate Mofetil and Lamivudine in the Treatment of Hepatitis B Virus Associated Nephritis

  21. 吗替麦考酚酯和环孢素A对大鼠慢性移植肾病细胞保护基因表达的影响

    Effect of Mycophenolate Mofetil Versus Cyclosporine A on Cytoprotective Genes Expression in Rat Kidney Allografts Undergoing Chronic Allograft Nephropathy

  22. 目的:评价吗替麦考酚酯胶囊在18名男性健康志愿者体内的生物等效性。

    Objective : To study the bioequivalence of the tested and reference mycophenolate mofetil capsules in 18 male healthy volunteers .

  23. 目的观察吗替麦考酚酯(骁悉)治疗系统性红斑狼疮的疗效及安全性。

    Objective To observe the effect and safety of mycophenolate mofetil ( cellcept ) in the treatment of systemic lupus erythematosus ( SLE ) patients .

  24. 两组患者术后1个月内急性排异反应的发生率比较:吗替麦考酚酯组及咪唑立宾组差异无显著性意义(5.5%,5.8%,P>0.05)。

    Rejection rate of the two groups one month after operation : There was no significant difference in the rejection rate compared Mycophenolate group with Mizoribine group ( 5.5 % , 5.8 % , P > 0.05 ) .

  25. 我不是告诉过你们,她是多么机敏和果断吗?吗替麦考酚酯治疗过敏吗?性紫癜肾炎的护理体会

    Did I not tell you how quick and resolute she was ? On the Nursing of Henoch-Schonlein Purpura Nephritis Treated with Mycophenolate Mofetil